https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-09-24 / Int J Hyperthermia 2012;28(8):707-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-09-24 / Int J Hyperthermia 2012;28(8):707-142012-09-24 00:00:002019-02-15 08:39:16Pathological complete response and sphincter-sparing surgery after neoadjuvant radiochemotherapy with regional hyperthermia for locally advanced rectal cancer compared with radiochemotherapy alone
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-09-11 / Int. J. Oncol. 2012 Nov;41(5):1601-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-09-11 / Int. J. Oncol. 2012 Nov;41(5):1601-92012-09-11 00:00:002012-09-11 00:00:00Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-09-10 / JOP 2012 Sep;13(5):502-13
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-09-10 / JOP 2012 Sep;13(5):502-132012-09-10 00:00:002012-09-10 00:00:00Two avirulent, lentogenic strains of Newcastle disease virus are cytotoxic for some human pancreatic tumor lines in vitro
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-09-01 / Cancer Immunol Immunother 2012 Sep;61(9):1415-24
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-09-01 / Cancer Immunol Immunother 2012 Sep;61(9):1415-242012-09-01 00:00:002023-03-07 13:03:07Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-21 / Hum Vaccin Immunother 2012 Sep;8(9):1179-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-21 / Hum Vaccin Immunother 2012 Sep;8(9):1179-912012-08-21 00:00:002019-02-15 08:52:22Immunotherapy in ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-20 / Oncologist 2012;17(10):1256-70
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-20 / Oncologist 2012;17(10):1256-702012-08-20 00:00:002019-02-15 08:39:54NK cells: key to success of DC-based cancer vaccines?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-19 / Curr Opin Virol 2012 Oct;2(5):629-35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-19 / Curr Opin Virol 2012 Oct;2(5):629-352012-08-19 00:00:002019-02-15 09:22:38The use of oncolytic viruses to overcome lung cancer drug resistance
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-10 / Korean J. Physiol. Pharmacol. 2012 Aug;16(4):243-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-10 / Korean J. Physiol. Pharmacol. 2012 Aug;16(4):243-72012-08-10 00:00:002019-02-15 08:53:36Morphologic evidence of anti-tumor specificity of T cells activated by denritic cells derived from peripheral blood mononuclear cells of thyroid cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-09 / Int. Immunopharmacol. 2012 Nov;14(3):252-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-09 / Int. Immunopharmacol. 2012 Nov;14(3):252-602012-08-09 00:00:002019-02-15 08:53:37Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-07 / Oncol. Rep. 2012 Oct;28(4):1131-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-07 / Oncol. Rep. 2012 Oct;28(4):1131-82012-08-07 00:00:002019-02-15 08:48:47Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial
